home All News open_in_new Full Article

Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec

Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US This represents the first filing of a novel non-chemotherapy approach in non-muscle invasive bladder cancer (NMIBC) treatment In the Japanese Phase 3 clinical trial, 75% complete response rate was achieved with single quarterly […]


today 3 d. ago attach_file Other

attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Science
attach_file Politics
attach_file Events
attach_file Events
attach_file Sport
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Events
attach_file Science
attach_file Events
attach_file Economics
attach_file Economics
attach_file Other
attach_file Economics


ID: 4243146435
Add Watch Country

arrow_drop_down